Drugs with this side effect
- 5-ASA: postmarketing, 3% - 5%
- 5-aza-2'-deoxycytidine: 16% - 27.3%
- 5-azacytidine: 10.9% - 18.6%
- Abarelix: 14.8%
- Anidulafungin: 10.7% - 12.8%
- BCNU: 2% - 9.17%
- BPTI
- Benicar-HCT
- CGP 19835A: common
- Cancidas: postmarketing, 11% - 12%
- Carfilzomib: 0% - 24%
- FK463: 5.5% - 7.25%
- Fe(III: 2.6% - 10.9%
- Gd-DTPA
- Glat copolymer
- Goserelin: 2.56% - 34%
- Histrelin
- Humalog
- ICI 182,780: 9% - 10.2%
- Insulin: 0.905% - 7.8%
- K779
- L-Dmp: infrequent
- LMWH: 0% - 6%
- LY146032: 6.67% - 13.8%
- Lantus: 1.79% - 22.7%
- Leuprorelin: 12% - 30%
- Lisinopril
- MDV3100: 1% - 15.4%
- Meropenem anhydrous
- NovoLog
- Nuvocid
- Octreotide
- Oestrogen
- PCI-32765
- Photofrin: 3.49% - 7%
- Photofrin II: uncommon
- Promacta
- Romidepsin: 0% - 9.92%
- SOM230: 10% - 11%
- SU5416
- Saxagliptin
- Signifor: 10% - 11%
- Supremon
- Triptorelin: 0% - 5%
- Trisequens
- UDCA: postmarketing, 8.3%
- VACV: 8% - 62%
- Vancocine
- Zyprexa Relprevv: common
- acamprosate
- acetaminophen
- acitretin
- acyclovir
- alendronate: postmarketing
- aliskiren: postmarketing, uncommon, 3.08% - 5.56%
- alpha-methyl-p-tyrosine
- alprazolam: postmarketing
- amantadine: very common
- ambrisentan: 17.2% - 28.4%
- amlodipine
- amlodipine besylate
- amphotericin B: 14.6% - 17.2%
- anagrelide: 8.5%
- anastrozole: 5% - 11.1%
- apraclonidine
- aripiprazole: 1% - 2%
- asenapine: 3%
- atazanavir: 7%
- atorvastatin: postmarketing
- avanafil
- azilsartan medoxomil
- baclofen: common, 0% - 3.33%
- bazedoxifene: common
- belinostat: 0% - 20%
- benazepril
- benazeprilat
- bendamustine
- bexarotene: common, 0% - 13.1%
- bicalutamide: 8% - 13%
- bimatoprost
- bisoprolol: 3% - 3.5%
- boceprevir: common
- bortezomib
- bosentan
- bosutinib
- brinzolamide
- bromocriptine: postmarketing, rare
- bupivacaine
- buprenorphine: 3% - 7%
- bupropion: postmarketing, infrequent
- cabazitaxel: 1%
- cabergoline: 0.905% - 8.5%
- candesartan
- candesartan cilexetil: 1.3% - 1.6%
- capecitabine
- capsaicin: uncommon
- carbamazepine
- carnitine: 3% - 6%
- carvedilol: 0.2% - 7%
- cefaclor
- cefditoren
- cefpodoxime
- ceftobiprole
- celecoxib: 1% - 3.5%
- cetirizine
- cevimeline
- chlorpromazine
- cidofovir
- cilostazol: 7% - 9%
- cinacalcet: 7%
- ciprofloxacin
- citalopram: rare, infrequent, uncommon
- cladribine: 2%
- clobetasol propionate: 0% - 0.833%
- clofarabine: common
- clopidogrel
- conivaptan: 1.6%
- copolymer 1
- cosyntropin
- crizotinib
- cytarabine: 0% - 25%
- d-telaprevir: uncommon
- dabigatran etexilate
- dabrafenib: 0% - 31%
- darifenacin: uncommon
- darunavir
- dasatinib
- deferiprone: postmarketing
- degarelix
- delamanid
- delavirdine
- demethyl
- deprenyl: frequent
- desmopressin
- desonide
- dexmedetomidine: 0% - 2%
- dexrazoxane
- diazepam
- diclofenac
- diltiazem: 2% - 5%
- docetaxel: 0%
- dofetilide
- dolasetron
- donepezil: frequent
- doxepin: rare
- doxorubicin: common
- doxycycline
- duloxetine: infrequent
- efavirenz
- eletriptan: infrequent
- eltrombopag
- entecavir: 16%
- eplerenone
- eprosartan
- eribulin
- eslicarbazepine
- eslicarbazepine acetate
- esomeprazole magnesium
- estradiol: 0% - 4.44%
- etoricoxib
- everolimus: very common, 0% - 44.9%
- exemestane: 6% - 7%
- ezetimibe
- felodipine
- fenofibrate
- fenoprofen
- fentanyl: common, 1% - 31.6%
- ferumoxytol: 2% - 3.2%
- fesoterodine: 0.7% - 1.2%
- finasteride: 1.3% - 2.6%
- fludarabine: 0% - 7%
- flunisolide
- fluoxetine: infrequent
- fluphenazine
- fluphenazine decanoate
- flutamide
- fluvastatin
- fluvoxamine: infrequent
- fondaparinux: uncommon
- formoterol: very rare, 3%
- fosinopril
- gabapentin: 0.5% - 44%
- gadobenate dimeglumine
- gadoversetamide
- galantamine
- ganciclovir
- gatifloxacin
- gefitinib: 2%
- gemcitabine: very common, 20%
- gemifloxacin: postmarketing
- glycerol
- hetastarch: postmarketing
- histamine
- hydrocodone: 1.37% - 2.65%
- hydromorphone: postmarketing, 2.24% - 5.46%
- hydroxocobalamin
- hydroxybutyrate: 0% - 3%
- ibandronate: 1.97%
- ibuprofen: 0.746% - 2.96%
- icodextrin
- iloprost
- imatinib: 0.3% - 40.9%
- indacaterol: common
- indapamide
- insulin detemir
- iodixanol
- iopromide
- ioversol
- ioxilan
- iron sucrose: 5.3% - 7.7%
- isosorbide dinitrate
- isosorbide-5-mononitrate
- isradipine
- itraconazole: postmarketing
- ivermectin: 3.2%
- ketoconazole
- lamotrigine: infrequent, 0% - 2%
- lansoprazole
- lasofoxifene: uncommon
- leflunomide
- lenalidomide: postmarketing, very common, 0% - 26.3%
- lercanidipine: uncommon, 1% - 1.1%
- letrozole: common, 3% - 9-17%
- leuprorelin acetate: 12.5%
- lisuride
- lithium carbonate
- lorcaserin: 4.69%
- lubiprostone: 1%
- medroxyprogesterone acetate: 2%
- megestrol
- meloxicam: 0% - 3.2%
- memantine: 2.01% - 2.69%
- meprobamate
- meropenem
- mesna: 6.7% - 8%
- metformin
- methylprednisolone sodium succinate
- methysergide
- metoprolol: postmarketing, common
- mifepristone: 26%
- milnacipran
- minoxidil
- mipomersen: 5%
- mirtazapine: 2% - 2.43%
- modafinil
- moexiprilat
- morphine: 3%
- moxifloxacin
- moxonidine
- mycophenolate mofetil: 27% - 64%
- mycophenolic acid: 10.7% - 64%
- naproxen
- nateglinide
- nebivolol: 1%
- nefazodone
- nelarabine
- niacin: postmarketing
- nicardipine
- nicorandil: uncommon
- nicotine
- nifedipine: postmarketing, 7%
- nilotinib: common, 0% - 17%
- nilutamide
- nisoldipine: 7% - 27%
- nitroglycerin
- nortriptyline
- ofatumumab: 1% - 9%
- olanzapine: common, 1% - 3%
- olmesartan: common, 0.379% - 1.19%
- olmesartan medoxomil
- olsalazine
- omeprazole: postmarketing, rare, uncommon
- oxaliplatin: 5% - 11%
- oxybutynin: 2.5% - 4%
- oxycodone
- paclitaxel
- paliperidone
- pantoprazole: very rare, postmarketing, rare
- parecoxib
- paricalcitol: 2% - 3.3%
- paroxetine: very rare, infrequent, uncommon
- pazopanib: 0% - 14%
- pentostatin
- perampanel: 1% - 2%
- pergolide: frequent, 7.4%
- perindopril
- perindopril erbumine
- perphenazine
- phencyclidine
- pilocarpine
- pioglitazone: postmarketing, 3.5%
- pomalidomide: 1.3% - 23.4%
- ponatinib
- posaconazole
- pramipexole: postmarketing, uncommon, common, 1.6% - 8%
- prasugrel: 2.7% - 3%
- pregabalin: 3.8% - 12%
- prochlorperazine
- progesterone
- prostacyclin
- quetiapine: frequent, 4%
- rabeprazole
- radium: 2% - 13%
- raloxifene: common, 3.3% - 5.2%
- raltegravir
- ramipril: 1.8%
- ranolazine
- rapamycin: 48% - 64%
- rasagiline: 7%
- rasburicase: 2.2% - 50%
- repaglinide
- retigabine
- retinoic acid: common, 52%
- ribavirin: common
- rifapentine
- rifaximin: 15%
- riluzole: 2.9% - 4.2%
- riociguat
- risedronate: 6.6% - 8.2%
- risperidone: 1% - 18%
- ritonavir
- rivastigmine: frequent
- rofecoxib
- ropinirole: infrequent, frequent, 2% - 4%
- ropivacaine: 0.6% - 2.4%
- rosiglitazone
- rotigotine: 2% - 9%
- salmon calcitonin acetate: postmarketing
- sertraline: postmarketing, infrequent, uncommon
- sibutramine
- sildenafil
- sitagliptin: postmarketing
- sitaxsentan: 8.72%
- sodium ferric gluconate
- solifenacin: postmarketing
- sparfloxacin
- strontium ranelate: postmarketing
- sunitinib
- tacrolimus: 0% - 48%
- tadalafil: 6%
- tamoxifen: 8-11% - 11.1%
- tamsulosin: 0.8%
- tazarotene
- teduglutide: 10%
- tegaserod
- telavancin: uncommon
- telithromycin
- telmisartan: 1%
- temozolomide: uncommon, 0.633% - 10.8%
- temsirolimus
- terazosin: 0.6% - 5.5%
- tesamorelin: 0% - 6.1%
- testosterone: postmarketing
- tetraen
- tetrahydrobiopterin
- thalidomide: 0% - 34.2%
- thioridazine
- thiothixene
- tiagabine: frequent
- ticagrelor
- tigecycline: 3.3%
- timolol
- tiotropium
- tofacitinib
- tolcapone
- tolterodine: postmarketing
- topiramate: 2%
- trabectedin
- tramadol
- trametinib: 0% - 31%
- trandolapril
- treprostinil
- trifluoperazine
- trospium chloride
- trovafloxacin
- valdecoxib: 2.1% - 3.2%
- valganciclovir: 1% - 17.7%
- valproate: 3% - 8%
- valrubicin
- varenicline
- vemurafenib: postmarketing, 0% - 23%
- verapamil: 1.7% - 3.7%
- vigabatrin: 5% - 7%
- vildagliptin: uncommon, common
- vinflunine
- voriconazole: very common, 0% - 4.86%
- vorinostat
- zaleplon: 1%
- ziconotide
- ziprasidone: infrequent
- zoledronic acid: uncommon, common, 1% - 5.6%
- zolmitriptan: rare
- zonisamide: infrequent
- zopiclone: frequent
- zuclopenthixol
|
Drugs with this indication
|